Ernie Blevins, an endocrinologist at the University of Washington, and his colleagues co-administered oxytocin and a low dose of tirzepatide, a dual agonist mimicking the effects of both GLP-1 and glucose-dependent insulinotropic polypeptide, to obese rats and discovered that together, they produced more pronounced weight loss than either treatment alone
Within these research contexts the blend has been used as a tool to probe somatotropic-axis signaling, lipolysis and visceral-adipose models, and recovery and body-composition endpoints in non-clinical settings
Adverse event reports Between February 2019 and December 2023, the FDA received 352 adverse event reports related to compounded GLP-1 drugs
The etiology of muscle cramps is complex and multifactorial
With years of experience serving health supplement wholesalers and global distributors, we focus on delivering innovative, high-quality solutions for the B2B market
Your healthcare provider may recommend alternative weight loss medications or treatments to keep the weight off
